Role of the gut microbiota and their metabolites in hemodialysis patients

Int J Med Sci. 2023 Apr 17;20(6):725-736. doi: 10.7150/ijms.82667. eCollection 2023.

Abstract

High serum phosphate levels in chronic kidney disease (CKD) are linked to adverse health outcomes, including cardiovascular disease, kidney disease progression, and all-cause mortality. This study is aimed to find out which microorganisms or microbial functions have a significant impact on higher calcium-phosphorus product (Ca x P) after they undergo hemodialysis (HD) treatment. Feces samples from 30 healthy controls, 15 dialysis patients with controlled Ca xP (HD), and 16 dialysis patients with higher Ca xP (HDHCP) were collected to perform in 16S amplicon sequencing. We found gut microbial composition was significantly different between hemodialysis patients and healthy controls. Three phyla including Firmicutes, Actinobacteria, and Proteobacteria were significantly enriched in hemodialysis patients. Although only one genus, Lachnospiraceae_FCS020_group, was significantly increased in higher Ca xP group, there were four metabolic pathways predicted by PICRUSt significantly increased in higher Ca xP group and associated with causing VC, including the pentose phosphate pathway, steroid biosynthesis, terpenoid backbone biosynthesis, and fatty acid elongation pathway. Characterizing dysbiosis of gut microbiome played the important role in hemodialysis patients.

Keywords: calcium-phosphorus product; chronic kidney disease; dysbiosis; gut microbiota.

MeSH terms

  • Feces
  • Gastrointestinal Microbiome* / genetics
  • Humans
  • Kidney
  • Renal Dialysis
  • Renal Insufficiency, Chronic* / microbiology
  • Renal Insufficiency, Chronic* / therapy